Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31315885.
- Also identified by DOI 10.1158/1078-0432.CCR-19-1753.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a <i>Listeria monocytogenes</i>-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.<i>See related article by Le et al., p. 5493</i>.
Medical subject headings
- Cancer Vaccines
- Carcinoma, Pancreatic Ductal
- Pancreatic Neoplasms